PLx Pharma Inc
F:1D5A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shanghai Hi-Tech Control System Co Ltd
SZSE:002184
|
CN |
PLx Pharma Inc
Other Current Liabilities
PLx Pharma Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PLx Pharma Inc
F:1D5A
|
Other Current Liabilities
$5.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Liabilities
$1.4B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Liabilities
$4.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Liabilities
$25B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Liabilities
$7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Liabilities
$8.5B
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
PLx Pharma Inc
Glance View
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
See Also
What is PLx Pharma Inc's Other Current Liabilities?
Other Current Liabilities
5.3k
USD
Based on the financial report for Sep 30, 2022, PLx Pharma Inc's Other Current Liabilities amounts to 5.3k USD.
